A new publication involving growth hormone-releasing peptide-6, known as GHRP-6, appeared on August 1, 2026. The study, titled "A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke," was published in Pharmacological Reports.
The paper is described as using a discovery-based proteomic approach, examining epidermal growth factor and GHRP-6 together in a model of acute ischemic stroke. No findings or outcomes from the study have been detailed here.
GHRP-6 remains classified as an unapproved compound used only in research settings. It has not been approved by regulatory authorities for clinical use in humans. This brief reports only the existence and basic details of the publication as provided.
Readers interested in the broader context of this compound, including its research history and regulatory status, can consult the compound overview for further information.